EAM
XENE icon

Eventide Asset Management’s Xenon Pharmaceuticals XENE Stock Holding History

Eventide Asset Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-413,906
Closed -$14.1M – 168
2023
Q3 		$14.1M Hold
413,906
– – 0.25% 104
2023
Q2 		$15.9M Sell
413,906
-227,294
-35% -$9.04M 0.27% 99
2023
Q1 		$22.9M Hold
641,200
– – 0.42% 73
2022
Q4 		$25.3M Hold
641,200
– – 0.5% 65
2022
Q3 		$23.1M Buy
641,200
+171,500
+37% +$6.17M 0.46% 70
2022
Q2 		$14.3M Buy
+469,700
New +$14.2M 0.31% 84
2021
Q3 		– Sell
-1,490,000
Closed -$27.7M – 162
2021
Q2 		$27.7M Hold
1,490,000
– – 0.37% 76
2021
Q1 		$26.7M Buy
1,490,000
+459,860
+45% +$7.79M 0.4% 80
2020
Q4 		$15.8M Sell
1,030,140
-243,960
-19% -$2.85M 0.24% 97
2020
Q3 		$14.1M Hold
1,274,100
– – 0.28% 92
2020
Q2 		$16M Hold
1,274,100
– – 0.35% 76
2020
Q1 		$14.4M Hold
1,274,100
– – 0.47% 66
2019
Q4 		$16.7M Hold
1,274,100
– – 0.47% 66
2019
Q3 		$11.5M Hold
1,274,100
– – 0.38% 73
2019
Q2 		$12.6M Buy
1,274,100
+653,409
+105% +$6.25M 0.38% 76
2019
Q1 		$6.31M Buy
620,691
+196,258
+46% +$1.66M 0.22% 85
2018
Q4 		$2.68M Buy
424,433
+109,433
+35% +$973K 0.12% 98
2018
Q3 		$4.16M Buy
+315,000
New +$3.65M 0.15% 103

Other funds holding XENE

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Eventide Asset Management's XENE Position: Q4 2023 in Review

Eventide Asset Management sold out of Xenon Pharmaceuticals (XENE) in Q4 2023, closing a stake of 413,906 shares — an estimated $14.1M sold.

Eventide Asset Management first reported a position in XENE in Q3 2018 and held it in 18 quarters. The position peaked at $27.7M in Q2 2021. 204 funds tracked by Wall St. Rank hold XENE as of Q4 2023.

  • Eventide Asset Management reported no remaining Xenon Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Eventide Asset Management sold 413,906 Xenon Pharmaceuticals shares in Q4 2023, an estimated $14.1M.
  • Eventide Asset Management first reported a position in Xenon Pharmaceuticals in Q3 2018 and held it in 18 quarters.
  • Eventide Asset Management's Xenon Pharmaceuticals position peaked at $27.7M in Q2 2021.
  • 204 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q4 2023.

Based on Eventide Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.